Research
Drotrecogin alfa (activated): real-life use and outcomes for the UK
-
* Corresponding author: Kathryn M Rowan kathy.rowan@icnarc.org
Intensive Care National Audit & Research Centre, Tavistock House, Tavistock Square, London WC1H 9HR, UK
Critical Care 2008, 12:R58 doi:10.1186/cc6879
Published: 22 April 2008Additional files
Additional file 1:
Data collection form completed for admissions that received DrotAA. Presented is the data collection form completed for patient admitted who received DrotAA.
Format: PDF Size: 74KB Download file
This file can be viewed with: Adobe Acrobat Reader
Additional file 2:
Timeline of the audit of DrotAA and other key events. Shown is the timeline of the audit of DrotAA and other key events.
Format: PDF Size: 39KB Download file
This file can be viewed with: Adobe Acrobat Reader
Additional file 3:
Balance between admissions receiving DrotAA and matched controls. Shown is the balance between patients admitted who received DrotAA and matched control patients.
Format: PDF Size: 15KB Download file
This file can be viewed with: Adobe Acrobat Reader
Additional file 4:
Propensity model for use of DrotAA. Shown is the propensity model for use of DrotAA.
Format: PDF Size: 21KB Download file
This file can be viewed with: Adobe Acrobat Reader